InMed to Participate in Fierce Biotech Webinar on Neuroinflammation in Alzheimer's Disease
InMed to Participate in Fierce Biotech Webinar on Neuroinflammation in Alzheimer's Disease
Vancouver, British Columbia–(Newsfile Corp. – October 24, 2024) – InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announced it will be participating in the upcoming Fierce Biotech webinar "Alzheimer's Outlook – Neuroinflammation, the Next Step," on November 12th, 2024.
不列颠哥伦比亚省温哥华——(新闻档案公司,2024年10月24日)——专注于开发专有小分子候选药物管道的制药公司InMed(纳斯达克股票代码:INM)(“InMed” 或 “公司”)今天宣布将参加即将于2024年11月12日举行的Fierce Biotech网络研讨会 “阿尔茨海默氏症展望——神经炎症,下一步”。
InMed's Senior Vice President of Preclinical Research and Development, Dr. Eric Hsu, will join a panel of experts to speak about recent trends in Alzheimer's disease research and the targeting of neuroinflammation to restrict disease progression. Details are as follows:
InMed临床前研究与开发高级副总裁Eric Hsu博士将加入专家小组,讨论阿尔茨海默氏病研究的最新趋势以及以神经炎症为目标以限制疾病进展的情况。详情如下:
Alzheimer's Outlook – Neuroinflammation, the Next Step
Date: November 12, 2024
Time: 2:00pm ET
Registration:
阿尔茨海默氏症展望——神经炎症,下一步
日期:2024 年 11 月 12 日
时间:美国东部时间下午 2:00
注册:
Discussion topics in this webinar include:
本次网络研讨会的讨论主题包括:
- the latest research into the causes of Alzheimer's disease
- the different therapeutic pathways being explored
- drugs in development and their pharmacological targets
- the pathophysiological effects of neuroinflammation in Alzheimer's disease
- 关于阿尔茨海默病病因的最新研究
- 正在探索的不同治疗途径
- 正在开发的药物及其药理靶标
- 阿尔茨海默病中神经炎症的病理生理学影响
Speakers for this event:
本次活动的发言人:
Phyllis Ferrell, DrPH, MBA (Moderator)
Dr. Phyllis Ferrell is the Chief Impact Officer at StartUp Health's Alzheimer's Moonshot. Formerly, she was the Global Head of External Engagement for Alzheimer's disease and neurodegeneration at Eli Lilly & Company, where she previously served as the leader of the Global Alzheimer's disease development team.
菲利斯·费雷尔,博士学位,工商管理硕士(主持人)
菲利斯·费雷尔博士是创业健康旗下阿尔茨海默氏月球的首席影响官。此前,她曾在礼来公司担任阿尔茨海默氏病和神经变性全球外部参与主管,此前她曾担任该公司的全球阿尔茨海默氏病开发团队负责人。
Barry Greenberg, PhD
Dr. Greenberg is an Associate Professor in the Department of Neurology at the Johns Hopkins University School of Medicine, where he is leading the development of an Alzheimer's Disease Translational Center, with the objective of integrating basic and clinical research to enable the development of effective therapies that will delay or prevent Alzheimer's at its earliest stages.
巴里·格林伯格博士
格林伯格博士是约翰·霍普金斯大学医学院神经病学系的副教授,他领导阿尔茨海默氏病转化中心的开发,目的是整合基础和临床研究,开发出有效的疗法,在阿尔茨海默氏症的早期阶段延缓或预防阿尔茨海默氏症。
David Morgan, PhD
Dr. Morgan is Director of the Alzheimer's Alliance and MSU Foundation Professor of Translational Neuroscience at Michigan State University. Dr. Morgan's research interests are Alzheimer's disease, aging and brain function. He is internationally recognized for his work on immunotherapy and gene therapy to treat Alzheimer-related pathologies.
大卫摩根,博士
摩根博士是阿尔茨海默氏症联盟董事兼密西根州立大学转化神经科学基金会教授。摩根博士的研究兴趣是阿尔茨海默病、衰老和大脑功能。他因在免疫疗法和基因疗法治疗阿尔茨海默氏症相关疾病方面的工作而获得国际认可。
Marwan Sabbagh, MD
Dr. Sabbagh is the Moreno Family Chair for Alzheimer's Research and Vice Chairman for Research and Professor of Neurology at the Barrow Neurological Institute in Phoenix Arizona. Dr. Sabbagh is first and foremost an experienced clinician, whose practice as a geriatric neurologist is world renowned. He has also been a leading investigator for Alzheimer's clinical trials for over 25 years.
马里兰州马尔万·萨巴格
萨巴格博士是亚利桑那州凤凰城巴罗神经学研究所的莫雷诺家族阿尔茨海默氏症研究主席、研究副主席兼神经病学教授。萨巴格博士首先是一位经验丰富的临床医生,他作为老年神经科医生的执业举世闻名。他还担任阿尔茨海默氏症临床试验的首席研究员超过25年。
Eric Hsu, PhD
Dr. Hsu is the Senior Vice President of Preclinical Research and Development at InMed Pharmaceuticals where he leads the Alzheimer's disease R&D program. He has 20+ years of research experience and is an expert in gene transfer and gene expression.
Eric Hsu,博士
许博士是InMed Pharmaceuticals临床前研发高级副总裁,领导阿尔茨海默氏病研发项目。他拥有20多年的研究经验,是基因转移和基因表达方面的专家。
About InMed's INM-901 for the potential treatment of Alzheimer's disease:
INM-901 is a small molecule drug candidate being developed as a potential treatment of Alzheimer's disease. INM-901 demonstrates multiple pharmacological effects in preclinical studies including neuroprotective effects, an ability to extend the length of neurites which is important for brain cell-to-cell communication, as well as a reduction in neuroinflammation. These preclinical studies were conducted in well-characterized study models of Alzheimer's disease.
关于InMed用于潜在治疗阿尔茨海默氏病的InM-901:
INM-901是一种小分子候选药物,正在开发作为阿尔茨海默氏病的潜在治疗方法。INM-901在临床前研究中表现出多种药理作用,包括神经保护作用、延长神经元长度的能力,这对于脑细胞间的交流很重要,以及减少神经炎症。这些临床前研究是在特征明确的阿尔茨海默氏病研究模型中进行的。
About InMed:
InMed Pharmaceuticals is a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates targeting the CB1/CB2 receptors. InMed's pipeline consists of three separate programs in the treatment of Alzheimer's, ocular and dermatological indications. Together with our subsidiary BayMedica, we are a global leader in the manufacturing, development and commercialization of rare cannabinoids and proprietary small molecule drug candidates. For more information, visit .
关于 InMed:
InMed Pharmaceuticals是一家制药公司,专注于开发针对CB1/CB2受体的专有小分子候选药物管道。InMed的产品线包括三个单独的项目,分别治疗阿尔茨海默氏症、眼部和皮肤病学适应症。我们与子公司BayMedica一起,是稀有大麻素和专有小分子候选药物的制造、开发和商业化的全球领导者。欲了解更多信息,请访问。
Investor Contact:
Colin Clancy
Vice President, Investor Relations
and Corporate Communications
T: +1.604.416.0999
E: [email protected]
投资者联系人:
科林·克兰西
投资者关系副总裁
和企业传播
T: +1.604.416.0999
E: [电子邮件保护]
Cautionary Note Regarding Forward-Looking Information:
关于前瞻性信息的警示说明:
This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking information") within the meaning of applicable securities laws. Forward-looking statements are frequently, but not always, identified by words such as "expects", "anticipates", "believes", "intends", "potential", "possible", "would" and similar expressions. Such statements, based as they are on current expectations of management, inherently involve numerous risks, uncertainties and assumptions, known and unknown, many of which are beyond our control. Forward-looking information is based on management's current expectations and beliefs and is subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Without limiting the foregoing, forward-looking information in this news release includes, but is not limited to, statements about: The upcoming webinar titled "Neuroinflammation, The Next Step"; INM-901's ability to treat AD and advancing our INM-901 drug candidate towards human clinical trials.
本新闻稿包含适用证券法所指的 “前瞻性信息” 和 “前瞻性陈述”(统称为 “前瞻性信息”)。前瞻性陈述通常以 “期望”、“预期”、“相信”、“打算”、“潜力”、“可能”、“将” 等词语和类似表述来识别,但并非总是如此。此类陈述基于管理层当前的预期,本质上涉及许多已知和未知的风险、不确定性和假设,其中许多是我们无法控制的。前瞻性信息基于管理层当前的预期和信念,存在许多风险和不确定性,这些风险和不确定性可能导致实际业绩与前瞻性陈述中描述的结果存在重大差异。在不限制上述内容的前提下,本新闻稿中的前瞻性信息包括但不限于以下方面的陈述:即将举行的名为 “神经炎症,下一步” 的网络研讨会;inm-901治疗AD的能力以及将我们的INM-901候选药物推进人体临床试验。
Additionally, there are known and unknown risk factors which could cause InMed's actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein. A complete discussion of the risks and uncertainties facing InMed's stand-alone business is disclosed in InMed's Annual Report on Form 10-K and other filings with the Securities and Exchange Commission on www.sec.gov.
此外,还有一些已知和未知的风险因素可能导致InMed的实际业绩、业绩或成就与本文所包含的前瞻性信息所表达或暗示的任何未来业绩、业绩或成就存在重大差异。InMed向美国证券交易委员会提交的10-K表年度报告以及其他在www.sec.gov上提交给美国证券交易委员会的文件中披露了对InMed独立业务面临的风险和不确定性的全面讨论。
All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.
此处的所有前瞻性信息均受本警示声明的全面限制,除非法律要求,否则InMed不承担任何修改或更新任何此类前瞻性信息或公开宣布为反映未来业绩、事件或发展而对本文包含的任何前瞻性信息进行任何修订的结果的义务。
To view the source version of this press release, please visit
要查看本新闻稿的源版本,请访问